PURPOSE OF THIS REVIEW
Since the US Food and Drug Administration (FDA) approved ferumoxytol (Feraheme, AMAG Pharmaceuticals, Waltham, MA, USA) to treat iron deficiency anemia in adults with chronic kidney disease (CKD) in 2009, the off-label use of this iron oxide nanoparticle compound by clinicians and researchers as a magnetic resonance imaging (MRI) contrast agent has rapidly grown. Ferumoxytol-enhanced imaging is feasible in patients with impaired renal function, a patient population in whom both gadolinium and iodinated contrast agents are contraindicated. Other attractive imaging features of i.v. ferumoxytol include a prolonged blood pool phase and delayed intracellular uptake. Furthermore, because iron is a naturally occurring element in the body, the administered iron enters the body's natural iron metabolic pathways. Thus, the use of ferumoxytol is not currently associated with concerns regarding long-term deposition, as is the case with brain deposition of gadolinium-containing agents.
There are 2 aims of this review: first, to draw attention to a viable option of contrast-enhanced cross-sectional imaging in patients with renal failure; therefore, Kidney International was chosen for publication, and second, to highlight the growing body of literature that explores a variety of clinical indications that suggest ferumoxytol has utility not only as an alternative to gadolinium-based contrast agents (GBCAs) but also as a specialized MRI contrast agent with unique properties.
The number of clinical trials that use ferumoxytol as a contrast agent is increasing. The coauthors are experienced in the imaging of the central nervous system (CNS), body, and cardiovascular system with ferumoxytol. Based on the recommendations of the coauthors, we collected relevant articles in the literature focusing on ferumoxytol over other ultrasmall superparamagnetic iron oxides (USPIOs) and highlighted the clinical applications rather than the preclinical investigations.
This article describes ferumoxytol administration, dosing, and timing for imaging applications, followed by organ-specific utilizations. We created an atlas (Supplementary Material 1) that more fully describes the application of ferumoxytol throughout the body and a table of relevant clinical publications (Supplementary Material 2) that use ferumoxytol, both of which can be found in the online supplement.
FERUMOXYTOL AS AN IRON REPLACEMENT
I.v. iron supplementation is important in patients with CKD owing to poor gastric absorption of oral iron. Insufficient absorption is related to the upregulation of hepcidin that occurs in CKD, 5 which is exacerbated by excessive iron losses. Although widely used, iron dextran, iron sucrose, and iron sodium gluconate have significant clinical limitations. Over the last decade, 3 new i.v. iron preparations have been developed that display tighter iron binding, allowing greater doses of iron to be given in a single administration. Along with ferric carboxymaltose and iron isomaltoside 1000, ferumoxytol has entered the therapeutic arena as an effective iron supplement. 5 Ferumoxytol has favorable physicochemical characteristics, potentially reducing amounts of circulating free iron. 6 Multiple studies have reported effective and safe treatments of iron deficiency with ferumoxytol. [7] [8] [9] 
FERUMOXYTOL IN MRI
Initially, ferumoxytol was developed as an MRI contrast agent because of its effectiveness in shortening T1 and T2 relaxation times. Licensing the drug as a therapeutic iron supplement was likely a strategic decision, but this compound still holds great potential as an MRI contrast agent. Satisfactory contrastenhanced imaging can be performed with doses as low as 1 mg/kg and as high as a 510 mg total dose. See Figure 1 for the potential imaging phases following i.v. administration.
Arterial-venous dynamic phase: T2*-based dynamic susceptibility contrast perfusion imaging of the brain requires only 1 mg/kg ferumoxytol and provides parametric maps of the brain similar to those achieved with a standard dose of gadolinium. 10 The lack of early contrast extravasation with ferumoxytol is beneficial in cardiovascular and peripheral vascular examinations, wherein T1-weighted images acquired using a 4-mg/kg bolus injection clearly show intravascular enhancement as hyperintense structures. Although there is no evidence that these small bolus injections carry a higher risk of adverse events, rapid injection of ferumoxytol is not currently recommended by the FDA. 11 Blood pool phase: One of the major advantages of nanoparticle imaging is the relatively long circulating time, with ferumoxytol displaying a plasma half-life of 14 to 21 hours. Even in highly permeable tumors, high-resolution imaging of the intravascular space can be achieved without visible background tissue enhancement. Steady-state blood volume mapping of the brain is a T2*-based technique that requires 3 to 7 mg/kg ferumoxytol, 12, 13 whereas T1-based steady-state angiography of the peripheral vessels is performed using 3 to 4 mg/kg. 14 Delayed phase: In brain lesions, slow leakage of ferumoxytol through the disrupted blood-brain barrier results in MRI signal changes peaking around 24 hours after ferumoxytol administration.
15 T1-weighted MRI shows signal increases similar to those observed with gadolinium. A signal decrease on T2/T2*-weighted images may represent high local iron concentration and/or intracellular uptake, which has many useful applications outside of the CNS. Indeed, the intracellular uptake of ferumoxytol in abdominal organs, lymph nodes, and vascular walls can be used to effectively delineate pathology in these areas. 16, 17 It is important to note that if a subsequent MRI is needed within 72 hours, ferumoxytol contrast enhancement may still be present in brain pathologies several days following administration. 15 In addition, decreased signal intensities in the liver, spleen, and bone marrow scans may persist for several months before returning to baseline.
FERUMOXYTOL METABOLISM AND CLEARANCE
Following extravasation, ferumoxytol nanoparticles are taken up by cells of the mononuclear phagocyte system (MPS, previously known as the reticuloendothelial system), primarily in the liver, spleen, and bone marrow. In the brain, macrophages or astrocytes contribute to ferumoxytol clearance. 18, 19 Within these phagocytic cells, the nanoparticles are stored in secondary lysosomes (Figure 2) . 19 The carboxymethyldextran coating is cleaved by dextranase and the cleaved coating is completely excreted by the kidneys and/or eliminated through feces. The iron core is incorporated into the body's iron stores and used for cell metabolism and hemoglobin synthesis. Unless the patient has known hemosiderosis or hemochromatosis, the administered iron during MRI examination (maximum, 510 mg) is safe, and no overloading occurs. Table 1 summarizes the physical, pharmacokinetic, and imaging properties of ferumoxytol compared with those of gadolinium.
FERUMOXYTOL SAFETY
On March 30, 2015, the FDA revised the prescribing information of Feraheme to include the addition of a boxed warning, which highlighted potential fatal and serious hypersensitivity reactions, including anaphylaxis. The warning emphasized the importance of trained personnel, appropriate medications being readily available, and monitoring patients for at least 30 minutes following administration to properly screen for hypersensitivity reactions. In the 3 premarketing clinical trials of Feraheme, [21] [22] [23] including 1164 patients, the aggregate rate of anaphylaxis was 0.2%. 14 The postmarketing trials had even better results; the largest trial with 8666 patients showed a serious adverse event rate of 0.2% and an anaphylaxis rate of 0.02%. 24 Recently, several studies described the diagnostic use of ferumoxytol in MRI, with no serious adverse events being reported. 20, [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] The frequency of ferumoxytol-related adverse events (10%-14.6%) and serious adverse events (0%-1%) were comparable in all investigations, with rates similar to those seen with ionic iodinated contrast agents, and were 10 times higher than gadolinium-related events. 35 The initial administration rate of a 510 mg bolus over 17 seconds was lowered to a slow infusion of 510-mg-diluted ferumoxytol over 15 minutes, as suggested by the FDA recommendation. By reducing the rate of administration, the frequency of these events may also be reduced.
Ferumoxytol has also shown an excellent safety profile in pediatric patients. 20 Typical doses of 1 to 5 mg/kg for imaging purposes are much lower than the therapeutic dose and do not have a significant effect on hemoglobin values. 20 Table 2 and Figure 3 indicate the most commonly used imaging sequences in the CNS.
CNS MRI WITH FERUMOXYTOL

Intracranial neoplasms
The use of ferumoxytol in MRI of primary brain tumors has been extensively studied. While lesion visualization with ferumoxytol is generally similar to that with GBCAs, differences in enhancement patterns may help in the differential diagnosis. Perfusion MRI and steady-state blood volume mapping may improve tumor grading by identifying the most malignant area for surgical targeting and therapy monitoring.
Lesion visualization. Contrast-enhanced MRI is routinely performed for the diagnosis of brain tumors, where the enhancement is the marker of the blood-brain barrier breakdown. Because extravasation of large molecules is slow, parenchymal enhancement is best seen in the delayed phase, 24 hours following ferumoxytol injection. 15 Contrast enhancement found on various clinically used T1-weighted MRI sequences improves border delineation and enables assessment of lesion internal morphology (Figure 4) . 36, 37 In primary malignant brain tumors, contrast enhancement with ferumoxytol is comparable with GBCA enhancement. No significant differences were found in the number of enhancing masses when gadolinium MRI and ferumoxytol MRI were compared in various primary brain tumors and metastatic lesions. 38 Differences in GBCA and ferumoxytol enhancement size and intensity may be present, 37 and they may reflect the differences in pathology, contrast agent dose, or timing of imaging. No difference was found in the enhancement size with the 2 contrast agents in metastatic lesions 38 or untreated glioma patients. 36 Decreased signal on T2-weighted images in the delayed phase may indicate high local ferumoxytol concentration or retention in tumorassociated macrophages. Delayed T1 and T2 enhancement together may help differentiate extracellular iron (e.g., tumor 
40,41
Differential diagnosis. Dural-based-enhancing masses may represent benign or malignant diseases, and there is no method to effectively distinguish between these pathologies solely with GBCAs. Preliminary data suggest that delayed T1 enhancement with ferumoxytol may help distinguish between meningioma and dural metastases when used in addition to GBCA. While all dural metastases strongly enhanced with ferumoxytol and GBCAs, meningiomas showed poor to no enhancement with ferumoxytol ( Figure 5 ). 42 Tumefactive demyelinating lesions are large lesions usually accompanied by mass effect and abnormal enhancement, mimicking brain tumors, posing a particular diagnostic dilemma in patients with or without an established diagnosis of multiple sclerosis (MS). 43 Definitive diagnosis is given after surgery and histopathologic confirmation. A noninvasive marker is highly desirable to assess this diagnostic dilemma. Ferumoxytol uptake in inflammatory lesions appears on delayed T1-and T2-weighted images 44 ; furthermore, perfusion MRI may help to differentiate tumors and demyelinating lesions, with relative cerebral blood volume (rCBV) being lower in tumefactive demyelinating lesions.
Blood volume-based lesion assessment. Measurement of the blood volume in tissues has important information regarding the level of vascularization. Small molecular weight contrast agents can only estimate blood volume using a dynamic first-pass technique. An intravascular contrast agent enables the measurement of blood volume using a steadystate technique by calculating signal differences between pre-and postcontrast (intravascular) images. This has the benefit of high spatial resolution because rapid acquisition is not required.
Dynamic susceptibility contrast perfusion-derived or steady-state cerebral blood volume (CBV) maps reflect brain tumor malignancy by revealing hypervascular, highly perfused tumor regions. rCBV (relative to a normal reference region) has been shown to correlate with survival and facilitates preoperative diagnosis by differentiating low-and highgrade tumors. 45 Moreover, elevated rCBV values can predict the transformation of low-grade gliomas into high-grade tumors 12 months before T1 enhancement appears. 46 Although these studies were performed using GBCAs, ferumoxytolderived rCBV values were in agreement with GBCA-derived values. 10 High-grade gliomas, metastases, and to a lesser degree, primary CNS lymphomas exhibit high rCBV values with dynamic susceptibility contrast or steady-state imaging, which can help differentiate them from demyelination, abscesses, and toxoplasmosis.
Intraoperative MRI and surgical targeting. More aggressive, hypervascular tumor regions with high rCBV values are the optimal sites for biopsy and can be identified using dynamic or steady-state perfusion imaging with ferumoxytol. However, dynamic perfusion methods have limited ability to differentiate between vessels and high tissue CBV, which compromises the assessment of small active tumor hotspots that could be the source of subsequent tumor progression and short survival. Because of its near distortion-free highresolution images, steady-state CBV mapping can overcome this limitation and may enable more precise targeting ( Figure 6 ). Late T2 enhancement with ferumoxytol has also been described to mark specific tumor areas and may again be useful for accurate biopsy targeting. 44 Finally, delayed enhancement with ferumoxytol enables intra-and postoperative assessment of a residual tumor without injecting additional contrast agent.
Treatment monitoring. After brain tumor therapy with radiation or chemoradiotherapy, an increased edema and contrast enhancement on MRI may either represent tumor progression (growing tumor mass, indicating failure of ongoing therapy) or pseudoprogression, which is defined as a treatment-induced subacute inflammatory reaction without underlying tumor growth. 47 Differentiating pseudoprogression from true tumor progression is a significant clinical problem. Response assessment according to the currently standard Response Assessment in Neuro-Oncology criteria is based on morphology and contrast enhancement and may delay or prevent proper therapy. 48 Similarly, antiangiogenic drugs affect the blood-brain barrier permeability without decreasing the tumor mass itself, which can lead to a pseudoresponse 49 that cannot be differentiated from a true response with the Response Assessment in Neuro-Oncology criteria. It is becoming apparent that a phenomenon similar to pseudoprogression occurs after an immune checkpoint blockade for cancer therapies. 50 This has led to the BBB, blood-brain barrier; CA, contrast agent; CBF, cerebral blood flow; CBV, cerebral blood volume; CNS, central nervous system; CT, computed tomography; DDx, differential diagnosis; dg, diagnosis; DSC, dynamic susceptibility contrast; Fe, ferumoxytol; GBCA, gadolinium-based contrast agent; GRE, gradient echo; HGG, high-grade glioma; LGG, low-grade glioma; MPRAGE, magnetization-prepared rapid gradient-echo; MRI, magnetic resonance imaging; MTT, mean transit time; PCNSL, primary central nervous system lymphoma; rCBV, relative cerebral blood volume; SE, spin echo; SI, signal intensity; SS-CBV, steady-state cerebral blood volume; Sx, surgery; T2 TSE, T2-weighted turbo spin echo; T2*w, T2*-weighted; TTP, time to peak; 3D, 3-dimensional.
r e v i e w development of immune-related response criteria to better identify cases of pseudoprogression, 51 although these criteria are not specific to the CNS. According to the immune-related Response Assessment in Neuro-Oncology criteria published in 2015, patients who have imaging findings that meet the Response Assessment in Neuro-Oncology criteria for progressive disease within 6 months of starting immunotherapy should undergo a confirmation of follow-up imaging (in 3 months) before defining the patients as nonresponsive to treatment. 52 The use of CBV mapping with ferumoxytol may help determine therapeutic efficacy in a variety of CNS tumors by differentiating highly vascular malignant tumor tissue from treatment-related neuroinflammation, which correlates with survival ( Figures 7 and 8) . 10, 53 We can now obtain high-resolution steady-state CBV images that differentiate regions of high vascularity and active tumor growth. 10, 13 Steady-state blood volume mapping with ferumoxytol is particularly helpful for imaging cortical lesions with an improved spatial resolution.
Neuroinflammation and demyelination
Delayed imaging with ferumoxytol allows the assessment of inflammation as an imaging biomarker. Few human MS investigations have been performed using ferumoxytol, but studies using other USPIOs such as ferumoxtran-10 have identified MS lesion phenotypes with the following enhancement patterns: (i) GBCAþ/delayed USPIO enhancement (USPIOþ), (ii) GBCAþ/USPIO-, and (iii) GBCA-/USPIOþ. The USPIO-specific lesions are of particular interest because they represent endothelial activation and diapedesis without blood-brain barrier disruption. Longitudinal studies demonstrate that in a fraction of GBCA-/USPIOþ MS lesions, delayed USPIO preceded GBCA enhancement by 1 month, suggesting extensive monocyte-macrophage extravasation in MS. 54 Ferumoxytol has been used to study neuroinflammatory processes associated with Japanese macaque encephalomyelitis, 55 a demyelinating disease of the nonhuman primate with strong similarities to MS. 56 A study by Tagge et al. 55 demonstrated substantially greater USPIOþ lesion volume than GBCAþ lesion volume during the acute Japanese macaque encephalomyelitis disease phase, indicating spatially and temporally extensive monocyte-macrophage migration into the CNS.
Farrell et al. 44 demonstrated delayed enhancement with ferumoxytol in patients with MS, primary CNS lymphoma, posttransplant lymphoproliferative disorder, acute print & web 4C=FPO Figure 6 | Steady-state cerebral blood volume (SS-CBV) maps using ferumoxytol offer higher spatial resolution and allow better identification of hypervascular areas for surgical targeting in glioblastoma patients. Compare the spatial resolution of CBV map using dynamic susceptibility contrast (DSC) perfusion-weighted imaging with a standard dose of gadolinium (DSC-CBV) (left) and the SS ferumoxytol CBV map (right) using ferumoxytol (3 mg/kg). The scan on the right more clearly demonstrates a central hypervascular area in the right occipital hemisphere with the greatest vascularity, which is likely the most malignant portion of the tumor. Images provided courtesy of Edward A. Neuwelt. (Figure 9 ), and chronic encephalitis; a higher number of lesions are visible with ferumoxytol than with GBCAs.
Future applications (ultrahigh field MRI [ Figure 10 shows an example how ferumoxytol improves the visualization of cerebral microvasculature at 7 T field strength], seizure imaging, functional MRI, and vascular imaging in the CNS) can be found in Supplementary Material 1.
BODY IMAGING WITH FERUMOXYTOL Liver and spleen
Metastases are the most common solid liver lesions (although benign hepatic hemangiomas are also frequent), and MRI is considered to be the definitive tool for differentiating these entities in an oncological setting. However, this task can be difficult when lesions are small or when hemangiomas are atypical or of the sclerosing subtype. In many cases, print & web 4C=FPO Figure 7 | Pseudoprogression can be diagnosed using perfusion magnetic resonance imaging (MRI) with ferumoxytol and correlates with overall survival. (a) Axial MRIs of a 47-year-old woman with glioblastoma. The patient underwent T1-weighted sequences after gadolinium administration, and T2-weighted postoperative images prior to chemoradiotherapy (CRT) are shown. Eight days after CRT completion, the patient's scans showed radiographic worsening, followed by further deterioration on follow-up MRI while the patient continued to receive adjuvant temozolomide chemotherapy. Although the updated Response Assessment in Neuro-Oncology criteria would indicate a true tumor progression, the blood volume of the lesion was low on ferumoxytol dynamic susceptibility contrast cerebral blood volume maps, which instead indicates pseudoprogression. The patient received only 3 courses of bevacizumab and continued adjuvant temozolomide. Substantial improvement is seen on the 5-month follow-up MRI after the completion of bevacizumab therapy. Seven years after the completion of CRT, the image indicates that the patient is stable without evidence of recurrence-progression (the patient is still on adjuvant temozolomide chemotherapy). (b) KaplanMeier estimates of overall survival with respect to the presence or absence of pseudoprogression. From Gahramanov S, Varallyay C, Tyson RM, et al. Diagnosis of pseudoprogression using MRI perfusion in patients with glioblastoma multiforme may predict improved survival. CNS Oncol. 2014;3:389-400. 53 Reproduced with permission of Future Medicine in the format Journal/magazine via Copyright Clearance Center. small hemangiomas can be differentiated from other lesions based on the retention of intravascular contrast agents such as gadofosveset trisodium or ferumoxytol on delayed scans. 57, 58 Significant negative (hypointense) T2 enhancement of normal liver parenchyma is seen within 10 minutes of i.v. ferumoxytol administration. Because ferumoxytol is taken up by the MPS, it has the potential to serve as a tool for measuring MPS dysfunction. Quantitative measures of MPS function, as estimated using dynamic imaging of ferumoxytol uptake in the liver, may prove to be useful predictors of graft dysfunction and rejection, although validations in humans are still pending. 59 
Pancreas
Computed tomography (CT) is the imaging method of choice for pancreatic diseases, including pancreatic adenocarcinoma, pancreatitis, and neuroendocrine tumors of the pancreas. MRI of the pancreas holds significant promise secondary to the many inherent contrast mechanisms, particularly those with novel contrast agents.
Blood vessel density is known to be markedly lower in pancreatic ductal adenocarcinoma compared with that in other malignancies, 60 which may explain its poor response to antiangiogenic therapies, thus making pancreatic ductal adenocarcinoma a poor choice for interrogation with dynamic techniques. Because of the long intravascular blood pool residence time, iron oxide nanoparticles offer a steady-state solution for the precise measurements of microvascular parameters, as demonstrated in preclinical studies, [61] [62] [63] [64] and are better imaging agents for pancreatic ductal adenocarcinoma. In subcutaneous xenograft models, MRI of magnetic nanoparticles provides a noninvasive, accurate assessment of fractional blood volume and vessel size index. [62] [63] [64] [65] [66] [67] [68] [69] [70] [71] [72] The delayed uptake of magnetic nanoparticles by macrophages 73 has also been a focus of MRI for multiple applications in the pancreas, including improved delineation of pancreatic adenocarcinoma, 17 and for quantifying inflammation in patients with early onset type 1 diabetes (Figure 11 ).
74,75
Staging of malignant tumors
The current anatomic imaging techniques for nodal staging (e.g., CT and MRI) rely on morphologic lymph node characteristics such as size, shape, and morphology, but sensitivity for differentiating malignant lymph nodes from benign ones remains low. 76 Sensitivity could be improved using USPIOs; however, most of the available data have been obtained with USPIOs other than ferumoxytol. 77, 78 Iron oxide particles are taken up by and retained in normal lymph nodes, resulting in signal loss on T2-and T2*-weighted images (Figure 12) . 79 When nodes are infiltrated with malignant cells, the nodal USPIO nanoparticle uptake capacity reduces and malignant nodes retain high signal intensity on T2*-weighted images. Optimal node T2*-weighted imaging contrast with ferumoxytol can be achieved 24 to 48 hours following injection (Figures 12 and 13 ).
16,79
Prostate
Nodal involvement is noted in 5% to 10% of patients with prostate carcinoma, but the detection sensitivity of CT and MRI remains lower than 30%. 80 Clinical experience with ferumoxytol-enhanced MRI for mapping metastatic lymph nodes in patients with prostate cancer is limited. Harisinghani et al. 16 reported a significant decrease in the signal-to-noise ratio in benign nodes on T2*-weighted images but little change in the signal-to-noise ratio in malignant nodes using ferumoxytol at a dose of 4 mg/kg. MRI was performed before and 5, 18, and 24 hours after ferumoxytol injection. The most appropriate dose of ferumoxytol is uncertain because lymph nodes in the pelvis are heterogeneous. Turkbey et al. 81 found that a higher dose of i.v. ferumoxytol (up to 7.5 mg/kg) was needed to completely darken the normal pelvic nodes compared with ferumoxtran-10.
Direct injection of ferumoxytol into the prostate (lymphography) has shown promise in mapping sentinel lymph nodes, as demonstrated in nonhuman primates. 82 Other potential applications in body imaging (breast and sentinel lymph node, colorectal, and adrenal gland MRI and 
Inflammation
Focal inflammation can mimic neoplasia. By labeling macrophages with ferumoxytol in vivo, macrophage trafficking can be detected and inflammatory lesions can be localized. 83, 84 Ferumoxytol-enhanced MRI is promising for assessing rheumatologic diseases and differentiating acute from chronic inflammatory kidney disease. [85] [86] [87] [88] Ferumoxytol-enhanced MRI has also been used for diagnosing osteomyelitis in the feet of patients with diabetes ( Figure 14) 89 and for assessing the activity of Crohn's disease. 90 
Pediatric MRI with ferumoxytol
Using ferumoxytol as an MRI agent in the pediatric population has similar potential benefits as those observed in adults. Specific advantages include separation of i.v. cannula placement/ ferumoxytol administration from the MRI scanning itself (which may improve the cooperation of the child if MRI is performed without anesthesia). 32 For pediatric brain tumor patients undergoing MRI with anesthesia, gadolinium and ferumoxytol in a single imaging session was well tolerated. 33 Three-dimensional contrast-enhanced MR angiography (MRA) applications in pediatric CKD patients have been reported to evaluate i.v. access placement, vascular thrombosis, cardiac and renal transplantation anastomosis, re-transplantation, and biliary/liver dysfunction, thereby eliminating concerns about nephrogenic systemic fibrosis. 30, 91 Finally, ferumoxytol may provide a higher level of confidence for the delineation of small vessels prior to surgery in body MRA. 32 Many types of lymphomas, soft tissue sarcomas, and bone sarcomas are staged with 18F-fluorodeoxyglucose positron emission tomography (18F-FDG-PET)/CT. 92 To provide a radiation-free alternative, whole-body diffusion-weighted MRI has been developed without the use of contrast agents. However, the use of ferumoxytol with this technique may be advantageous ( Figure 15 ). 28 
VASCULAR MRI WITH FERUMOXYTOL
Traditional contrast-enhanced MRA employs timed, first-pass imaging of a gadolinium bolus, focused on the arterial or venous territory of interest. For the majority of GBCAs, the volume of distribution is the extracellular fluid space, which is quickly accessed after the arterial first pass. Therefore, the time window for a pure or predominantly vascular phase is very short, and the acquisition can be technically challenging. Gadofosveset is a GBCA with an extended blood residence time because of reversible binding to serum albumin. However, compared with ferumoxytol, gadofosveset has a much shorter intravascular half-life (30 minutes vs. 14-21 hours), and at any given time, approximately 20% of gadofosveset is distributed in the extracellular fluid space. Moreover, gadofosveset is being withdrawn from production such that by the end of 2016, ferumoxytol will be the only intravascular MRI contrast agent available for human use in the US.
Imaging in patients with a vascular disease is challenging; many (20%-30%) patients are diabetic with associated No blackening of node or node is hyperintense to surrounding tissue; heterogeneous or homogenous architecture Node has central high signal with darkening alone the peripheral rim; heterogenous architecture Partial darkening whereby more than 50% of the node has an area of high signal intensity; heterogenous architecture Less than 50% of node has high signal intensity; heterogenous architecture Node having an overall dark signal other than a central or hilar area of fat seen on T1 sequence; heterogenous architecture Node having an overall dark signal with speckles of subtle granularities; homogenous architecture
Node having an overall dark signal intensity; homogenous architecture difficult vein access 93 and many (20%-40%) have CKD, which can prohibit the use of iodine-and gadolinium-based contrast agents. 34, 94 Ferumoxytol is a very attractive option in these patients and can be used without the need for bolus timing or complex image acquisition schemes. Ferumoxytol's excellent safety profile has already been established in patients with chronic renal insufficiency, although it must always be used with close physiological monitoring.
In recent years, there have been several reports regarding the successful use of ferumoxytol in vascular imaging in adults and children with renal failure. 30, 32, 34, 57, 91, 95, 96 The studies suggest that ferumoxytol provides similar or improved quality images compared with GBCAs, without the concerns of long-term gadolinium accumulation. [1] [2] [3] [4] Some of the potential applications of ferumoxytol in vascular imaging are summarized in Table 3 .
Cardiac imaging
To date, there have been very few reports regarding the use of ferumoxytol in patients with ischemic heart disease. In patients with acute myocardial infarction, Alam et al. 97 and Yilmaz et al. 98 showed macrophage activation in injured myocardium. These authors exploited the effects of ferumoxytol in causing signal loss owing to its effect on T2 values and did not address vascular enhancement because of the shortening of T1 values. In congenital heart disease, accurate anatomic assessment is important for surgical or interventional planning. Conventional first-pass MRA and 2-dimensional cardiac cine methods provide limited definition of intracardiac structures. In contrast, ferumoxytol supports the acquisition of 4-dimensional images of the beating heart with 4-dimensional, multiphase, steadystate imaging with contrast enhancement (Figure 16 ). 99 Similarly, comprehensive motion-compensated highly accelerated 4-dimensional flow MRI with ferumoxytol enhances the quality of 4-dimensional flow information with reduced respiratory motion artifacts in children with congenital heart disease. 100, 101 The imaging goals for most congenital heart diseases include the quantification of blood flow in the great vessels, determination of cardiac chamber volumes and contractility, and assessment of segmental anatomy. Typically, this requires a lengthy MRI scan with over an hour of repeated breath holding under anesthesia, with specialized r e v i e w technologists and physicians on hand to prescribe customized planes for image acquisition. A compelling advantage of ferumoxytol is that it enables volumetric temporally resolved high-resolution imaging without breath holding. 99 Furthermore, a free-breathing volumetric comprehensive MRI yielding flow, function, and anatomic assessment in less than 10 minutes has been achieved. 100 Additionally, ventricular mass may be quantified with this same technique. 101 As a result, no special operator knowledge of cardiac anatomy is required, and the duration of anesthesia and the complexity of the procedure of congenital heart MRI can be greatly reduced. These techniques stand to revolutionize the approach to MRI in children with complex congenital heart diseases.
Aortic imaging
Aortic imaging can be performed with CT angiography, noncontrast MRI, or gadolinium-enhanced MRA. Blood volume, flow measurements, and morphologic assessments can be made with contrast-enhanced MRA using a combination of time-resolved and steady-state images. Inflammation in the aortic wall can be potentially assessed using in vivo macrophage labeling with ferumoxytol, which is not available with gadolinium-enhanced imaging. Inflammation plays a key role in the progression and vulnerability of rupturing atherosclerotic plaques in many arterial territories. The presence of inflammation can also predict vessel patency. 102, 103 Additionally, because of its long intravascular half-life, ferumoxytol can be used in the detection of aortic endoleaks after endovascular aneurysm repair. A systematic review showed that MRA detected almost twice as many endoleaks as CT angiography. 104 Iron oxide-enhanced MRA (either with ferumoxytol or ferucarbotran) may be advantageous for demonstrating endoleaks. 105, 106 Visceral arteries and arteriovenous fistulas Patients with end-organ ischemia in the abdominal vasculature often have diabetes and renal insufficiency. Therefore, ferumoxytol may be a useful agent for assessing renal artery stenosis, pre-and posttransplantation vessel patency, and new venous access. In pre-and postrenal and liver transplantation patients, ferumoxytol has been used to assess vascular integrity. 30, 95 The frequent occurrence of venous occlusion in these patients and the requirement to confirm or re-establish venous access make highresolution venous imaging with ferumoxytol invaluable (Figure 17) . 91 Most studies regarding pre-fistula assessments involve pediatric patients because this group benefits the most from ferumoxytol-enhanced MRA. In a feasibility study using Other applications in vascular imaging (carotid and peripheral artery imaging and MR venography) can be found in the Supplementary Material 1.
DISCUSSION
In this review, we draw attention to ferumoxytol as a contrast agent for cross-sectional imaging in patients with renal failure and highlight the various clinical indications in which ferumoxytol may not only be an alternative to GBCAs but also may be a specialized contrast agent with unique properties. These include the extended blood pool phase and uptake into the MPS in the delayed phase, where nanoparticles are metabolized as iron.
Ferumoxytol has been approved by the FDA for iron replacement in 2009, and it is available for off-label clinical use. A large and growing body of literature has been reviewed in this manuscript showing the potentials of ferumoxytol imaging. Although most available evidence is based on single-center studies, pilot studies, retrospective analyses, and preclinical results, there are new multicenter, multiplatform studies being designed (clinicaltrials.gov, NCT02359097). Application for FDA approval for the use of ferumoxytol as an imaging agent is in preparation, which would further ease its widespread use in MRI.
Limitations
Besides known hypersensitivity or iron metabolic disorders, there is no absolute contraindication for ferumoxytol in MRI, and importantly, it is safe in patients with renal impairment. Vascular visualization improves early after administration, whereas late enhancement visualizes parenchymal-intracellular enhancement, which may require an additional visit, posing a logistical limitation with MRI scheduling. A signal change in the brain may persist from a few days to a week. Uptake in the liver, spleen, and bone marrow may alter MRI signal for months; therefore, radiologists must be aware of any prior history of i.v. iron oxide use. While hypersensitivity reactions occur, the incidence of serious ferumoxytol-related hypersensitivity is very low, and new FDA guidelines aim to further improve patient safety.
CONCLUSION
In conclusion, there are numerous potential applications of ferumoxytol in MRI throughout the body, including the CNS, various organs outside of the CNS, and cardiovascular system. Whether used in cases wherein GBCAs are contraindicated or for applications that are currently outside the scope of GBCAs, ferumoxytol has shown sufficient promise to warrant 
